Employers Covering Weight-Loss Drugs Could Nearly Double
The number of US employers who cover obesity medications, including Wegovy from Novo Nordisk that belongs to a class of GLP-1 drugs, could nearly double next year, according to a survey.
The number of US employers who cover obesity medications, including Wegovy from Novo Nordisk that belongs to a class of GLP-1 drugs, could nearly double next year, according to a survey.
Warning letters to PCPs regarding overprescribing of antipsychotics for patients with dementia were associated with a decrease in prescriptions.
Families may feel more comfortable requesting food, housing, and other assistance if they don’t first need to disclose socioeconomic hardships.
The diabetes/weight loss drug semaglutide is associated with a significantly greater risk for repeat operations in patients with diabetes who require lumbar surgery.
Dr Roger Henderson provides seven top tips for primary care practitioners on the recognition, assessment, and management of this chronic autoimmune condition
Are you screening all adults for viral hepatitis, as recommended by the Centers for Disease Control and Prevention (CDC)? Join 2 experts in a discussion…
Dr Claire Davies identifies seven key learning points for primary care on managing long-term effects of COVID-19
Cardiology and nephrology experts present insights into the associations between ASCVD and CKD, inflammation, and potential for anti-inflammatory therapies.
Are You Able to Recognize and Treat Murine Typhus?
Dr George Moncrieff discusses best practice in the recognition and treatment of psoriasis and related comorbidities in children, providing five top tips for management in…
Two copies of APOE4 may be more than just a risk factor for AD; the pair may cause the disease in 15%-20% of cases.